Carestream Health Reports Partnership with Ziehm Imaging Americas

April 19, 2021

Carestream Health in partnership with Ziehm Imaging announced the addition of a mobile C-arm into its growing innovative product portfolio.

Known as the Ziehm Vision RFD C-arm, this surgical imaging system will further enhance Carestream’s mobile and fluoroscopic product offerings to benefit even more healthcare providers. The system will be available in the U.S. and Canada in 2021.

The Vision RFD C-arm offers a 25kw generator, in either a 20.5 x 20.5 cm or 31 x 31 cm field of view flat-panel CMOS digital detector, allowing for broad procedural work including vascular, cardiac, spine ortho-trauma and pain management, in addition to many general surgical applications. The system’s Advanced Active Cooling enables extended case times beyond traditional air-cooled systems. It also provides an intuitive graphical interface that benefits technologists with reduced training time as well as improved productivity.

“The partnership with Carestream Health confirms Ziehm Imaging’s industry-leading technology,” said Nelson Mendes, President and CEO of Orthoscan and Ziehm Imaging Inc. “As a result of this partnership, we’re able to provide Carestream and its customers with one of the most innovative C-arms on the market. The Ziehm Vision RFD delivers advanced surgical care with the Ziehm Usability Concept, provides exceptional image quality and helps to reduce exposure significantly with the next-generation SmartDose, thereby providing a very unique package.”

Ziehm Vision RFD systems will be available for sale and service through Carestream. The company’s Sales & Service team—working in collaboration with Ziehm Imaging—will provide responsive support to all valued customers. Carestream Service is widely recognized for its outstanding customer satisfaction and prompt support.

“The addition of the Ziehm C-arm to our medical imaging portfolio—backed by Carestream’s deep experience in radiology and fluoroscopy applications—is another example of our commitment to meet the evolving needs of our customers and their patients,” said Steve Romocki, Worldwide Product Line Manager for Radiology Systems at Carestream.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”